TPTX News and Press, Turning Point Therapeutics Inc. From 04/09/21

SAN DIEGO, April 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced new preclinical data supporting the ongoing development of three of its dru...

Turning Point Therapeutics (TPTX) posted positive initial clinical data from the ongoing Phase 1/2 SWORD-1 study of its RET inhibitor drug candidate, TPX-0046, for the treatment of certain types of cancer.In the study, a total of 21 patients with RET-altered non-small cell lung canc...

Preliminary Clinical Activity Shown, With Tumor Regression in 4 of 5 TKI-Naïve Patients Including 2 Confirmed Partial Responses Preliminary Clinical Activity Shown, With Tumor Regression in 3 of 9 TKI-Pretreated Patients Across 6 Dose Finding Cohor...

Sheila Gujrathi has stepped down as chair of the board of Turning Point Therapeutics (TPTX).Garry Nicholson, a current board member, has been named interim chair.Jacob Chacko has also left the board and has been replaced by Barbara Bodem.Turning Point shares closed up 5.7% to $94.59...

Barbara Bodem Joins Board, Appointed Chair of Audit Committee Garry Nicholson Appointed as Interim Board Chair SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation the...

Turning Point Therapeutics'(TPTX) CFO, Yi Larson, to resign from her position as Chief Financial Officer to pursue another opportunity.The move is effective March 31, 2021.Brian Baker, the Company’s Senior Vice President, Finance and Administration, and principal accounting officer, wi...

With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.Noting a ~110% YoY rise in deal volumes in February including ~221% YoY growth in U.S. mid-cap deals,...

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced today that four abstracts featuring three of its drug candidates will be presente...

Turning Point Therapeutics, Inc. (TPTX) Q4 2020 Results Earnings Conference Call March 01, 2021, 4:30 pm ET Company Participants Jim Mazzola - Senior Vice President, Communication and Investor Relations Athena Countouriotis - President, Chief Executive Officer Yi Larson - Executive Vice Presi...

The following slide deck was published by Turning Point Therapeutics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Turning Point Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation